{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-054498","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.744528+00:00","generated_at":"2026-06-28T13:10:25.183508+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbCellera announces U.S. government purchase of 614,000 doses of bamlanivimab/etesevimab for $1.29B","bullets":["Lilly will supply 614,000 additional doses no later than January 31, 2022; minimum 400,000 by December 31, 2021.","Total agreement value is $1.29 billion for bamlanivimab with etesevimab, discovered by AbCellera.","The antibody therapy has treated over 535,000 patients in the U.S., potentially preventing 25,000 hospitalizations.","AbCellera receives royalties from Lilly on sales of bamlanivimab and etesevimab."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-054498","json":"https://secwatch.observer/filing/0001564590-21-054498.json","markdown":"https://secwatch.observer/filing/0001564590-21-054498.md","text":"https://secwatch.observer/filing/0001564590-21-054498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021054498/0001564590-21-054498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459021054498/abcl-8k_20211102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:10:25.183508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}